Barometer Capital Management Inc. Boosts Holdings in Genmab A/S Sponsored ADR $GMAB

Barometer Capital Management Inc. lifted its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 842.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,400 shares of the company’s stock after purchasing an additional 37,900 shares during the period. Barometer Capital Management Inc.’s holdings in Genmab A/S were worth $1,138,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC grew its stake in shares of Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Genmab A/S in the first quarter valued at $34,000. Brown Brothers Harriman & Co. raised its stake in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Finally, Founders Capital Management boosted its holdings in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Wolfe Research assumed coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. Finally, Truist Financial started coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.21.

Genmab A/S Stock Up 1.6%

Shares of NASDAQ GMAB opened at $28.36 on Wednesday. The company has a market capitalization of $17.68 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The business has a 50-day moving average of $26.68 and a two-hundred day moving average of $28.35. Genmab A/S Sponsored ADR has a 1 year low of $21.00 and a 1 year high of $35.43.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.